Conference on Retroviruses and Opportunistic Infections (CROI 2022)

Sotrovimab reduces hospitalization, death in patients with COVID-19 regardless of serostatus

Elaine Soliven, 20220323000000

Treatment with sotrovimab reduces the risk of all-cause hospitalization or death in patients with COVID-19 who are at high risk of progression to severe disease, regardless of anti-SARS-CoV-2 serostatus, according to a study presented at CROI 2022.

Booster COVID-19 vacc cuts breakthrough infection risk, particularly in individuals with no immune dysfunction

Roshini Claire Anthony, 20220317180001

Receipt of a booster dose of the COVID-19 vaccine reduces the risk of breakthrough COVID-19 infections* compared to full vaccination only, particularly among individuals without immunosuppressed/compromised conditions (ISC), according to a US study presented at CROI 2022.

Post-COVID sequelae conditions identified, could help establish definition

Roshini Claire Anthony, 20220308180001

Patients diagnosed with COVID-19 could have an increased risk of certain conditions up to 120 days post-diagnosis, a finding which could help establish the definition of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), according to a study presented at CROI 2022.

Universal HCV screening in pregnancy: A step toward reducing transmission?

Roshini Claire Anthony, 20220301180001

Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.

Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH

Audrey Abella, 20220221151710

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

IM noninferior to IV sotrovimab for COVID-19

Audrey Abella, 20220217083414

In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.